NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC:AXIM), a world leader in cannabinoid research and development, today announced the appointment of Mauricio Javier Gatto-Bellora to the Company’s Board of Directors.

Gatto-Bellora has more than three decades of experience in the pharmaceutical, biochemistry and cosmetics industries throughout the world with a specialty in strategizing and implementing plans for international success. His business background encompasses several prominent companies, including Mary Kay, Inc., MonaVie, Natura and Allergan, spanning multiple countries including Mexico, Brazil and Argentina. While working with Natura, he served as the CEO-International, CEO-Brazil & Latin America, President-Latin America and General Manager-Argentina and was responsible for more than $5 billion in sales. Gatto-Bellora was also the President, CEO and Chairman of the Board of MonaVie, selling the company’s nutritional products in 46 countries.

“Mauricio Javier Gatto-Bellora has an extensive track record of leading companies through international expansion and will be valuable to AXIM as the company continues to expand and move forward with our clinical development program,” said John W. Huemoeller II, CEO of AXIM^® Biotech. “AXIM is moving forward in its pipeline of pharmaceutical and nutraceutical products with some products slated to hit the market as soon as next quarter. We look forward to what we can accomplish internationally with Gatto-Bellora’s expertise.”

Currently, Gatto-Bellora is the founder and President of Hair Ventures, LLC and founder and CEO of Daumdeuman, LLC. Gatto-Bellora holds a doctorate degree in Pharmaceutical Sciences & Biochemistry from the University of Buenos Aires, and a postgraduate degree in International Business from INSEAD.

“It humbles me to join a company such as AXIM® Biotech that continues to prove itself as a cannabis pharmaceutical industry leader and prioritizes the quality of its products to bring consumers top-tier treatments,” said Mauricio Javier Gatto-Bellora, Member of the Board of Directors. “As AXIM continues its international expansion, my previous business background will drive me to assist the company in achieving its goals.”

Gatto-Bellora will serve as a member of the Company’s Audit, Compensation and Nominating and Governance Committees in place of Blake N. Schroeder who resigned his position.

To learn more about AXIM® Biotechnologies, Inc., visit http://aximbiotech.com/.

About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.